Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Apr 16, 2021
Editas Medicine (EDIT, $34.90) shares got a sell rating  from Goldman Sachs

Editas Medicine (EDIT, $34.90) shares got a sell rating  from Goldman Sachs

Editas Medicine  shares got a sell rating  from Goldman Sachs as the latter initiated coverage on the stock.

Goldman Sachs analysts set a price target of $20 a share, a Wall Street low, on the biotech shares. According to the analysts, the risk-reward dynamic was skewed negatively for the company.

Goldman analyst Madhu Kumar mentioned in a note that initial results from Editas’ experimental Crispr gene editing product EDIT-11 in a rare eye disease may not lead to adequate productive editing to meaningfully improve patients' vision. Also affecting the rating is competition from ProQR Therapeutics for treatment of Leber's congenital amaurosis. 

On the other hand, Kumar was more optimistic on Apellis Pharmaceuticals   and Dicerna Pharmaceuticals. The analyst has price targets of $130  on Apellis and $48 on Dicerna – both Wall Street highs. Both got buy ratings.

 

Related Ticker: EDIT

Aroon Indicator for EDIT shows an upward move is likely

EDIT's Aroon Indicator triggered a bullish signal on March 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 162 similar instances where the Aroon Indicator showed a similar pattern. In of the 162 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 20, 2026. You may want to consider a long position or call options on EDIT as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on February 20, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

EDIT moved above its 50-day moving average on March 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EDIT crossed bullishly above the 50-day moving average on March 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EDIT moved out of overbought territory on March 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on March 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.749) is normal, around the industry mean (29.967). P/E Ratio (0.000) is within average values for comparable stocks, (40.439). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.795). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (5.345) is also within normal values, averaging (309.856).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 26 to 123.47B. VRTX holds the highest valuation in this group at 123.47B. The lowest valued company is KRBPQ at 26.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 21%. TVGN experienced the highest price growth at 3,580%, while IMMP experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was -50% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 83
Price Growth Rating: 58
SMR Rating: 92
Profit Risk Rating: 95
Seasonality Score: -18 (-100 ... +100)
Related Portfolios: BIOTECHNOLOGY SECTOR
View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EDIT showed earnings on March 09, 2026. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Interact to see
Advertisement
Dive into the complexities of the miscellaneous sector as we uncover the trajectories of major players like $YETI, $TUP, and $DOV. Despite a significant 20.4% gain in just a month, not everything is as rosy as it seems. Read on to decipher our sell recommendations and where these tickers might be headed next.
Financial Learning Models (FLMs) and machine learning (ML) to operate at unprecedented speeds. These agents, now optimized for 5-minute (M5) timeframes, have demonstrated extraordinary annualized returns, with the top agent exceeding +160%.
AI-Driven Market Insights A.I.dvisor’s latest analysis compares SPY and VOO, two leading ETFs, revealing near-identical year-to-date (YTD) gains of 9.82% for SPY and 9.87% for VOO, a 99% parity.
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents, delivering real-time trading signals and sophisticated money management for retail and institutional traders. Powered by Financial Learning Models (FLMs) and machine learning, these agents operate across 5-, 15-, and 60-minute timeframes, achieving annualized returns of up to 145% on select portfolios.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the exceptional performance of its AI Trading Agents, achieving annualized returns of up to 162%, profitable trade percentages as high as 90.51%, and a robust profit factor across multiple assets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, proudly announces the exceptional performance of its AI Trading Agents, delivering annualized returns of up to 188% on a 5-minute timeframe.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced the launch of its advanced Pattern Search Engine (PSE), a revolutionary platform that scans 39 distinct trading patterns across stocks, penny stocks, ETFs, crypto, and forex.
#artificial_intelligence
AI trading bots represent the pinnacle of financial technology innovation, transforming how traders and investors interact with global markets.
#artificial_intelligence
As a financial analyst, writer, and AI specialist, I've always pushed for innovations that merge artificial intelligence with actionable trading tools. In the fast-paced world of modern markets, where volatility demands quick decisions, Tickeron's new "My Trades Aggregator (from AI Robots Followed)" aggregator stands out as a revolutionary feature.
#artificial_intelligence#trading
Tickeron, a leading provider of AI-driven trading solutions, is thrilled to announce the exceptional performance of its AI Trading Agents, delivering outstanding results across multiple high-profile stocks.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technologies, today announced groundbreaking results from its AI Crypto Trading Virtual Agents. These innovative tools provide real-time trading signals, integrated money management, and customizable balances, all powered by advanced machine learning algorithms operating on 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technologies, today announced the launch of its advanced AI Trading Brokerage Agents. These cutting-edge tools deliver real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
This remarkable rally represents far more than typical market volatility – it signals a fundamental transformation in investor sentiment toward AI connectivity infrastructure and the critical role of semiconductor-based solutions in enabling next-generation artificial intelligence systems
Tickeron, a leader in AI-driven financial tools, today announced the launch of its comprehensive subscription package combining AI Trading Robots for cryptocurrencies with Real-Time Patterns (RTP) analysis.
#artificial_intelligence
Kinross Gold Corporation (KGC), a leading Canada-based gold producer, yielded approximately 2.1 million gold equivalent ounces in 2024.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technologies, today announced impressive results from its AI Trading Agent focused on the iShares U.S. Aerospace & Defense ETF (ITA). Over 123 days, the agent achieved an annualized return of +48%, generating $14,104 in closed trades profit and loss (P/L).
#artificial_intelligence
Tickeron, a pioneer in AI-powered trading solutions, today unveiled groundbreaking results from its 5-minute AI Trading Agent focused on Hubbell Incorporated (HUBB). In just 68 days, the agent delivered an impressive +98% annualized return and $12,899 in closed trades profit/loss (P/L), showcasing the transformative power of machine learning in stock trading.
#artificial_intelligence
In the fast-paced world of stock trading, where market volatility can swing fortunes overnight, Tickeron emerges as a beacon for investors seeking reliable guidance. As a leading provider of AI-powered trading solutions,
#artificial_intelligence
The company's journey from a struggling clean energy stock trading near multi-year lows to a market leader commanding a $12.9 billion valuation demonstrates the convergence of technological breakthroughs, strategic partnerships, regulatory tailwinds, and the explosive growth of AI-driven data centers that require reliable, on-site power solutions.
Palantir Technologies (NASDAQ: PLTR) has delivered one of the most remarkable performances in the technology sector during 2025, with its stock price surging approximately 145% from the April 7, 2025 low of $66.12 to the September 9, 2025 closing price of $162.36.